Novo Nordisk (NVO) Stock Gains as Wegovy Drug Gets FDA Nod for Liver Disease – TipRanks

Business News

  1. Novo Nordisk (NVO) Stock Gains as Wegovy Drug Gets FDA Nod for Liver Disease  TipRanks
  2. Novo Advances After US Clears Wegovy for Liver Disease  Bloomberg.com
  3. Wegovy® approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis  PR Newswire
  4. Novo Nordisk shares are rising. The FDA approves another use for Wegovy.  MarketWatch
  5. Novo Nordisk’s Wegovy gets accelerated US approval for liver disease MASH  Reuters

Source: Business News

/by